LAPREM: LAparoscopic Preventive PRErectal Mesh

Sponsor
University Hospital, Lille (Other)
Overall Status
Recruiting
CT.gov ID
NCT03766048
Collaborator
Ministry of Health, France (Other)
834
9
2
45.6
92.7
2

Study Details

Study Description

Brief Summary

Urogenital prolapse is a frequent and invalidating pathology in women, involving the anterior vaginal wall and the uterus in most cases. Posterior vaginal wall prolapse is present in only 50% of cases. Surgery is an option for women with troublesome prolapse. A woman's lifetime risk of undergoing surgery for pelvic organ prolapse (POP) surgery by the age of 80 is around 19%. Laparoscopic sacrocolpopexy (LS) with synthetic non-absorbable mesh is considered the gold standard, with a composite success rate of 85% at one year (Prospere study). Based on early experience and historical habits, a prerectal mesh was used to be systematically placed in the rectovaginal space, in addition to the anterior and apical mesh placed in the vesicovaginal space, in order to prevent de-novo posterior prolapse (reported rates up to 33%).

The benefit of preventive prerectal mesh is questionned on the basis of a single retrospective study comparing 68 LS with double-mesh (anterior & posterior, DM) to 32 LS with a single anterior mesh (SAM): posterior recurrence rates were respectively 5.9 vs. 31.3% (p<0,01), and total recurrence rates 16.2 vs. 43.8% (p<0.01). However, as this difference was not significant in the subgroup of patients without associated cervicocystopexy, the authors concluded that the risk of posterior failure was only due to the cervicocystopexy itself (anti-urinary incontinence procedure which has been abandoned since).

On the other hand, a prerectal mesh increases the risk for specific complications: rectal injury (up to 3%), anal pain (up to 25%), mesh exposition (up to 2%). Furthermore the posterior mesh increases the procedure by a minimum of 30 minutes (Robolaps study, unpublished data). The rate of de-novo obstructed defecation after LS with prerectal mesh is reported up to 25%. It could be explained by the mesh itself, but also by nerve injuries during the dissection of the rectovaginal space and rectal stalks.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Single-Anterior-Mesh, SAM
  • Procedure: Double-Mesh, DM
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
834 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Non-inferiority Randomized Double Blind Controlled Trial Comparing Results of Laparoscopic Sacrocolpopexy With or Without Preventive Prerectal Mesh in Women Operated for Urogenital Prolapse Without Significant Posterior Vaginal Wall Prolapse
Actual Study Start Date :
Sep 11, 2019
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single-Anterior-Mesh, SAM

Procedure: Single-Anterior-Mesh, SAM
laparoscopic sacropexy is only performed with the anterior mes

Sham Comparator: Double-Mesh, DM

Procedure: Double-Mesh, DM
laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space

Outcome Measures

Primary Outcome Measures

  1. Composite criteria of success at 2 years follow-up [at 2 years after the intervention]

    Composite criteria of success at 2 years follow-up: no symptom of vaginal bulge, no prolapse beyond the hymen (>0 cm), no reintervention for prolapse recurrence. Its advantage is that it considers only recurrences that are symptomatic or needing a reintervention. It is strongly linked with women satisfaction after prolapse surgery.

Secondary Outcome Measures

  1. Anatomical results [at 2 years]

    Anatomical results will be based on clinical evaluation of patients at 2 years follow-up using the POP-Q system, with a specific evaluation of posterior vaginal wall with measures of the Bp point

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women with a urogenital prolapse (anterior wall and/or uterus or vaginal apex) stage = 2 (Ba and/or C points ≥ - 1 cm using the POP-Q system),

  • without significant posterior vaginal wall prolapse (Bp < -1 cm when apical prolapse is reduced using a retractor leaving the posterior vaginal wall free),

Exclusion Criteria:
  • Previous surgical repair for Pelvic Organ Prolapse

  • Any associated prolapse requiring any non-authorized additional surgical repair (Authorized additional surgical procedures are hysterectomy, ovariectomy, adnexectomy, salpingectomy, myomectomy, or suburethral vaginal tape.)

  • Wish for future pregnancy

  • Lack of health insurance

  • Woman not reading French or unable to consent

  • Woman under law protection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Estaing Clermont-Ferrand France
2 Ch Dunkerque Dunkerque France
3 Hopital Saint-Louis - La Rochelle La Rochelle France
4 Clinique Du Pre Le Mans France
5 Hop Jeanne de Flandre Chu Lille Lille France 59037
6 Hopital Saint Vincent - Saint Antoine Lille France 59037
7 Chu de Nice Hopital de L'Archet Nice France
8 Chu Nimes - Nimes Nîmes France
9 Chi Poissy St Germain Site de Poissy Poissy France

Sponsors and Collaborators

  • University Hospital, Lille
  • Ministry of Health, France

Investigators

  • Principal Investigator: Jean-Philippe LUCOT, MD,PhD, University Hospital, Lille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT03766048
Other Study ID Numbers:
  • 2017_74
  • 2018-A01487-48
  • PHRCN-17-0226
First Posted:
Dec 5, 2018
Last Update Posted:
Sep 14, 2020
Last Verified:
Sep 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Lille
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2020